Advancing Cancer Research in Northern India
The Cancer Research Institute (CRI) is a premier non‑profit organization dedicated to pioneering discoveries in oncology, improving patient outcomes, and training the next generation of cancer specialists across Uttar Pradesh and Uttarakhand.
Request a Consultation
Active Research Projects
Clinical Trials Conducted
Patients Served Annually
Published Papers (2023)
About Cancer Research Institute
Founded in 2005, the Cancer Research Institute (CRI) has established itself as a leading force in oncology research and patient care in Northern India. With state‑of‑the‑art facilities in Noida (Uttar Pradesh) and a satellite center in Dehradun (Uttarakhand), we integrate cutting‑edge laboratory research with compassionate clinical practice.
Our mission is to reduce the burden of cancer through innovative research, early detection strategies, personalized treatment protocols, and comprehensive patient support. We collaborate with international institutions like the National Cancer Institute (USA) and the Tata Memorial Centre to bring global expertise to our region.
Our Vision
A world where every cancer patient in India has access to the most advanced, evidence‑based care and where continuous research leads to sustainable cures.
Basic & Translational Research
We investigate cancer biology, genetics, immunology, and drug resistance mechanisms to identify novel therapeutic targets.
Clinical Excellence
Our multidisciplinary tumor boards and clinical teams provide personalized treatment plans using the latest protocols.
Education & Training
We offer fellowship programs, workshops, and continuous medical education for oncology professionals across India.
Our Research Divisions
CRI’s research is organized into synergistic divisions that work together to tackle cancer from multiple angles.
This division focuses on understanding the genetic and epigenetic alterations that drive cancer initiation and progression. Our team uses next‑generation sequencing, CRISPR‑based screens, and bioinformatics to identify driver mutations in cancers prevalent in the Indian population, such as oral, breast, and cervical cancers.
Recent Breakthrough: Identification of a novel fusion gene in a subset of locally advanced breast cancers that predicts response to PARP inhibitors. This discovery, published in Nature Cancer India, is now being validated in a multi‑center trial.
Learn MoreWe engineer and test novel immunotherapies, including CAR‑T cells, cancer vaccines, and immune checkpoint modulators. Our lab has developed a proprietary platform for generating patient‑specific tumor‑infiltrating lymphocytes (TILs) for solid tumors.
Current Trial: Phase I/II trial of a personalized neoantigen vaccine combined with anti‑PD1 therapy for advanced melanoma (CRI‑MEL01). Preliminary data shows a 60% objective response rate.
From high‑throughput screening of natural product libraries to rational drug design, this division aims to develop new chemical entities and repurpose existing drugs for oncology indications. We have a strong collaboration with the Indian Institute of Chemical Technology.
Pipeline Highlight: CRI‑101, a first‑in‑class small molecule inhibitor of a DNA repair enzyme, has received orphan drug designation from the Central Drugs Standard Control Organisation (CDSCO) for glioblastoma.
Research Publications
Access our latest research papers, white papers, and annual reports.
View All PublicationsClinical Trials & Patient Participation
CRI conducts Phase I‑IV clinical trials across multiple cancer types. We are committed to ethical research, informed consent, and patient safety. Search for open trials suitable for your condition.
| Trial ID | Cancer Type | Phase | Intervention | Status | Action |
|---|---|---|---|---|---|
| CRI‑LUNG‑2024 | Non‑Small Cell Lung Cancer | III | Immunotherapy + Chemotherapy | Recruiting | Inquire |
| CRI‑BRCA‑2023 | HER2‑Negative Breast Cancer | II | Targeted Therapy (ADC) | Active, not recruiting | Closed |
| CRI‑GLIO‑2024 | Glioblastoma | I/II | Gene Therapy | Recruiting | Inquire |
Comprehensive Patient Care
Our Patient‑Centered Approach
From diagnosis through survivorship, our team provides holistic care addressing medical, psychological, and social needs. We offer financial counseling, nutritional support, pain management, and palliative care services.
Multidisciplinary Tumor Board
Weekly reviews by surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists to create consensus treatment plans.
Survivorship Programs
Long‑term follow‑up, lifestyle modification counseling, and rehabilitation to improve quality of life after treatment.
Supportive & Palliative Care
Specialized teams manage symptoms, provide psychosocial support, and ensure dignity and comfort for advanced‑stage patients.
Tele‑Oncology Services
Virtual consultations, second opinions, and follow‑ups for patients across Uttar Pradesh and Uttarakhand.
Latest News & Events
CRI Scientist Wins ICMR Award 2024
Dr. Anjali Mehta received the prestigious Indian Council of Medical Research Award for her work on cervical cancer screening in rural UP.
May 15, 2024
Read more
New Advanced Surgical Wing Inaugurated
The Chief Minister of Uttar Pradesh inaugurated our new robotic surgery and intraoperative radiation therapy facility.
April 22, 2024
Read more
Free Screening Camp in Uttarakhand Villages
Over 1,200 individuals screened for oral, breast, and cervical cancer in a week‑long camp in collaboration with the state health department.
March 30, 2024
Read moreContact Us
Get in Touch
We are here to answer your questions about research, clinical trials, patient services, or partnerships.
Main Campus (Uttar Pradesh)
Cancer Research Institute, Medical Research Park, Sector 62, Noida, Uttar Pradesh 201301, India
Satellite Center (Uttarakhand)
CRI Dehradun, Doon Medical College Campus, Patel Nagar, Dehradun, Uttarakhand 248001, India
Phone:
+91‑120‑4567890 (Main)
+91‑135‑4567891 (Dehradun)
Email:
[email protected] (General)
[email protected] (Clinical Trials)
Licenses & Accreditations
Cancer Research Institute is registered under the Societies Registration Act, 1860. Recognized by the Department of Scientific and Industrial Research (DSIR). NABH Accredited Hospital. CDSCO Approved Clinical Trial Site. License No: UP‑MED‑045‑2024. ISO 9001:2015 Certified.
Disclaimer
The information provided on this website is for educational purposes only and is not a substitute for professional medical advice. Please consult a qualified healthcare provider for diagnosis and treatment. © 2024 Cancer Research Institute. All rights reserved.